 At present, lipid lowering therapy, usually with a HMG-CoA reductase inhibitor or statin, is recommended therapy for selected patients with type 2 diabetes mellitus DM. The use of statins for primary prevention of CVD is not clear. Some primary prevention studies have found a statistically significant benefit but others have not CARDS and ASPEN. 